Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Sonnet BioTherapeutics Holdings ( (SONN) ) is now available.
On January 21, 2025, Sonnet BioTherapeutics announced the expansion of its Phase 1 SB101 clinical study to evaluate SON-1010 in combination with trabectedin in adult patients with advanced solid tumors, specifically targeting soft-tissue sarcomas. The expansion follows successful monotherapy dose escalation and aims to explore immune-oncology impacts at a maximum tolerated dose. The new cohort will assess the potential for enhanced progression-free survival and improved therapeutic outcomes for soft-tissue sarcoma patients. Enrollment is underway with results expected in late 2025, potentially positioning SON-1010 for a Phase 2 study and establishing a new treatment option for soft-tissue sarcoma.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company that develops targeted immunotherapeutic drugs using its proprietary Fully Human Albumin-Binding (FHAB) platform. This platform is designed to enhance the safety and efficacy of biologic drugs by targeting tumor and lymphatic tissues, optimizing the therapeutic window for immune modulating biologics.
YTD Price Performance: -3.75%
Average Trading Volume: 1,452,280
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.63M
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.
